The European Medicines Agency (EMA) has concluded its review of retinoid medicines and has recommended updating measures for pregnancy prevention and including a warning on the possible risk of neuropsychiatric disorders.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) examined the available data and confirmed that all oral retinoids can have harmful effects on the unborn child and therefore must not be used during pregnancy. In addition, the oral retinoids acitretin, alitretinoin and isotretinoin must not be taken by women able to have children unless the conditions of a new pregnancy prevention programme (PPP) are met. For the oral retinoids bexarotene and tretinoin, current measures are considered appropriate for pregnancy prevention. Although the risk is low with topical retinoids, the PRAC recommended that topical retinoids must also not be used during pregnancy and in women planning to have a baby.
The companies that market acitretin, alitretinoin and isotretinoin will conduct a study to assess the effectiveness of the updated measures.
While acknowledging that the evidence is limited, the PRAC also recommended that the prescribing information for all oral retinoids should include a warning about the risk of neuropsychiatric disorders, and patients and families should be made aware of the signs and symptoms to watch for.
New data shows “depressingly poor” management of headache disorder in European countries.
The Eurolight initiative gathered data on headache disorders using surveys in 10 countries in the European Union (EU) – Austria, France, Germany, Ireland, Italy, Lithuania, Luxembourg, Netherlands, Spain and the UK. The sample included 3,466 adults with migraine, of whom 1,175 reported frequent migraine (>5 days/month).
In population-based samples, only 9.5-18.0 per cent of participants with migraine had seen a GP and just 3.1-15.0 per cent had consulted a specialist. Between 3.4 and 11 per cent were receiving triptans, with Spain outlying at 22.4 per cent. Across the sample, 1.6-6.4 per cent were receiving preventative medication, with Spain again outlying at 13.7 per cent. Proportions of patients receiving triptans and preventative medicines were higher in GP-based samples (13.6-24.5% and 4.4-9.1%, respectively).
Participants with migraine who had consulted specialists (3.1-33.8%) were receiving the best care by these indicators; those treated by GPs (9.5-29.6%) fared less well, and those self-medicating (48.0-84.2%) were inadequately treated, the figures suggest.
Writing in The Journal of Headache and Pain, the authors say: “The picture is therefore not encouraging: as reflections of reach and adequacy of headache services for headache, these findings indicate depressingly poor performance in the EU.”
Even slightly lower scores on the Apgar scale could predict the risk of a later diagnosis of cerebral palsy (CP) or epilepsy, new research published in The BMJ suggests.
Researchers in Sweden analysed data from the national Medical Birth Registry for over 1.2 million infants born between 1999 and 2012. Data on maternal and pregnancy characteristics and diagnoses of CP and epilepsy were obtained by individual record linkages of nationwide Swedish registries.
They found an Apgar score of 9 or lower at five or 10 minutes conferred increased risks of CP, whereas risks of epilepsy were increased among those with Apgar scores of 7-8 or less at five and 10 minutes. The authors noted that even an Apgar score of 9 at five minutes and a 10-minute score of 10 was associated with a slightly increased hazard ratio for CP, while the risk of epilepsy was increased in infants with a full Apgar score at five minutes and a 10-minute score of nine.
The authors said the findings “provide justification for assigning all newborns an Apgar score at one, five, and 10 minutes and continuing active neonatal resuscitation of infants who are mildly compromised at five minutes”.
Attention-deficit hyperactivity disorder (ADHD) is a common childhood behavioural disorder. Systematic reviews indicate that the community prevalence globally is between 2% and 7%, with an average of around 5%. At least a further 5% of children have substantial difficulties with overactivity, inattention, and impulsivity that are just under the threshold to meet full diagnostic criteria for ADHD. Estimates of the administrative prevalence (clinically diagnosed or recorded) vary worldwide, and have been increasing over time. However, ADHD is still relatively underrecognised and underdiagnosed in most countries, particularly in girls and older children. ADHD often persists into adulthood and is a risk factor for other mental health disorders and negative outcomes, including educational underachievement, difficulties with employment and relationships, and criminality. The timely recognition and treatment of children with ADHD-type difficulties provides an opportunity to improve long-term outcomes. This Review includes a systematic review of the community and administrative prevalence of ADHD in children and adolescents, an overview of barriers to accessing care, a description of associated costs, and a discussion of evidence- based pathways for the delivery of clinical care, including a focus on key issues for two specific age groups—younger children (aged ≤6 years) and adolescents requiring transition of care from child to adult services.
The US Food and Drug Administration (FDA) has cleared for marketing the Embrace smart watch (Empatica Inc) for seizure tracking and epilepsy management.
The Embrace smart watch uses advanced machine learning to identify convulsive seizures and sends an alert via text and phone message to caregivers.
Embrace was tested in a clinical study involving 135 patients with epilepsy who were admitted to epilepsy monitoring units for continuous monitoring with video electroencephalography while simultaneously wearing the device, which records electrodermal activity.
Researchers collected 6530 hours’ worth of data over 272 days, including 40 generalized tonic-clonic seizures. Embrace’s algorithm detected 100% of the seizures, confirmed by independent epilepsy experts. The device also records sleep, rest, and physical activity data.
“The FDA approval of the Embrace device to detect major convulsive seizures represents a major milestone in the care of epilepsy patients,” Orrin Devinsky, director of the Comprehensive Epilepsy Center at NYU Langone in New York City, said in a news release from the company.
“Tragically, more than 3000 Americans die each year from sudden unexpected death in epilepsy (SUDEP) and the Embrace offers the potential to alarm family members and caretakers that a tonic-clonic seizure is occurring. The scientific evidence strongly supports that prompt attention during or shortly after these convulsive seizures can be life-saving in many cases,” Dr Devinsky added.
Embrace was approved in Europe for seizure monitoring and alerts in April 2017.
The US Centers for Disease Control and Prevention estimates that about 3.4 million people in the United States have epilepsy, including 470,000 children.
Gary R. Zirpoli, Susan E. McCann, Lara E. Sucheston-Campbell, Dawn L. Hershman, Gregory Ciupak, Warren Davis, Joseph M. Unger, Halle C. F. Moore, James A. Stewart, Claudine Isaacs, Timothy J. Hobday, Muhammad Salim, Gabriel N. Hortobagyi, Julie R. Gralow, G. Thomas Budd, Kathy S. Albain, Christine B. Ambrosone
Background Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches. In a cohort of breast cancer patients receiving paclitaxel as part of a clinical trial (SWOG 0221), we examined the use of dietary supplements both before diagnosis and during treatment in relation to CIPN.
Methods At registration to S0221, 1225 breast cancer patients completed questionnaires regarding the use of multivitamins and supplements before and at diagnosis. A second questionnaire at six months queried use during treatment. Supplement use was evaluated in relation to CIPN, assessed via the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 3.0) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed with logistic regression for the CTCAE analyses and ordinal regression for the FACT/GOG-Ntx analyses.
Results Multivitamin use before diagnosis was associated with reduced symptoms of CIPN (CTCAE-adjusted OR = 0.60, 95% CI = 0.42 to 0.87; FACT/GOG-Ntx-adjusted OR = 0.78, 95% CI = 0.61 to 1.00). Use during treatment was marginally inversely associated with CIPN (CTCAE-adjusted OR = 0.73, 95% CI = 0.49 to 1.08; FACT/GOG-Ntx-adjusted OR = 0.77, 95% CI = 0.60 to 0.99). Other supplement use, either before diagnosis or during treatment, was not statistically significantly associated with CIPN.
Conclusions Multivitamin use may be associated with reduced risk of CIPN, although individual dietary supplement use did not appreciably affect risk. Multivitamin use could be a surrogate for other related behaviors that are the actual drivers of the association with reduced CIPN. Without prospective randomized trials of vitamin supplementation, recommendations for use or changes to clinical practice are clearly not warranted.
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent consequence of treatment with paclitaxel. Symptoms of CIPN reduce quality of life and are potentially long lasting. Additionally, CIPN may lead to dose reduction or discontinuation of chemotherapy,[1,2] potentially affecting treatment efficacy and future risk of recurrence.
Few data are available to predict which patients will develop CIPN or if there are effective approaches to prevention. Dose per cycle, cumulative dose, and treatment frequency have all been shown to be positively associated with CIPN,[3–6] as was smoking in one study. Studies of genetic polymorphisms and CIPN have not been conclusive.[8–14] Small trials showed that supplementation with omega-3 fatty acids and vitamin E[16,17] reduced risk of CIPN. In a randomized trial with breast cancer patients, acetyl-L-carnitine was associated with increased risk.
After receiving a cancer diagnosis, patients may be motivated to make lifestyle changes that they believe will improve their health, reduce their risk of recurrence, and reduce the side effects of treatment.[19–22] Often, dietary supplements are used to complement traditional cancer therapies, with reports of patients’ use of dietary supplements postdiagnosis ranging from 67% to 87%. In the Pathways study, a prospective cohort of breast cancer survivors, 60% of women began using a dietary supplement following diagnosis. Given the high prevalence of supplement use by survivors, understanding the effect that supplements may have on treatment outcomes, including CIPN, is important. To investigate if supplement use prior to and during chemotherapy for breast cancer was associated with the experience of CIPN, we used data from the Diet, Exercise, Lifestyle, and Cancer Prognosis (DELCaP) study. The DELCaP study, embedded in a large cooperative group therapeutic trial of dosing regimens for treatment of high-risk breast cancer, was designed to examine lifestyle factors, particularly the use of vitamin supplements before diagnosis and during chemotherapy, in relation to treatment outcomes.
DELCaP was a questionnaire-based study ancillary to a breast cancer intergroup phase III clinical trial (SWOG 0221; NCT00070564) that compared dosing schedules of doxorubicin, cyclophosphamide, and paclitaxel. Figure 1 shows the design of S0221, with numbers limited to only those who participated in DELCaP.
Study design schematic limited to participants with questionnaire data (n = 1340). Doxorubicin/cyclophosphamide was received according to one of the following schedules: every two weeks for six cycles, every two weeks for four cycles, or weekly for 15 cycles. Paclitaxel was received every two weeks for six cycles or weekly for 12 cycles. A = doxorubicin; C = cyclophosphamide; T = paclitaxel.
We embedded a description of the DELCaP study and permission to contact patients into the therapeutic consent for S0221, and all participants provided written informed consent. A form with patient contact information was faxed to our staff when patients were registered to the trial, which enabled us to provide them with questionnaires for completion prior to initiation of chemotherapy. Before sending questionnaires, study staff telephoned patients to describe the DELCaP study. If questionnaires were not returned in a timely manner, staff telephoned as a reminder and sent out replacement questionnaires, or answered questions if needed. Patients who returned incomplete questionnaires were also contacted to provide that information over the telephone, thus ensuring complete data for all questions from the majority of patients. S0221 accrual began in October 2003, with approval to conduct the DELCaP study in June 2005; thus, data on supplement use were available from patients who were enrolled during or after 2005 (n = 2014). Among these patients, 1726 consented to participation in DELCaP (85.7%), and 1482 of these patients (85.8%) completed and returned the first questionnaire. The baseline questionnaire collected data on supplement use and other lifestyle factors prior to and at diagnosis, before treatment was initiated. Approximately six months after study registration, when taxane treatment was scheduled to be completed, a second questionnaire was sent to participants, querying about lifestyle and supplement use during cancer treatment. As with the first questionnaire, patients who did not return the questionnaire or who submitted incomplete information were contacted to provide assistance in completing the questionnaire. Of the 1225 DeLCaP participants who completed the first questionnaire assessing supplement use prior to and at diagnosis and who were randomly assigned to one of the treatment arms and received paclitaxel, 1068 completed the second questionnaire (87.2%) assessing use during chemotherapy. The 157 patients who did not return the second questionnaire had lower education and were younger, less likely to be non-Hispanic white, and more likely to have smoked compared with those who completed the second questionnaire (data not shown). This study was approved by the institutional review boards at Roswell Park Cancer Institute and at all participating institutions that enrolled patients to S0221.
In S0221, CIPN events were monitored and reported with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0. Grade 3 neuropathies include sensory loss or paresthesia interfering with activities of daily living. Grade 4 indicates disabling sensory loss that interferes with function. Study sites participating in S0221 were required to report grade 3 or higher neuropathy due to treatment. Therefore, we classified CIPN as a dichotomous variable (grades 3–4 vs grades 0–2).
For additional measures of patient-reported neuropathy representing a broader range than CTCAE grades 3 and 4, the second DELCaP questionnaire administered after chemotherapy also included the FACT-Taxane. In the 11-item FACT/GOG-Neurotoxicity subscale (FACT/GOG-Ntx), symptoms including numbness and discomfort in hands and feet, joint and muscle pain, and trouble feeling and walking are assessed via a five-point scale. Scores are categorized into tertiles, where tertile 1 indicates no or few symptoms, tertile 2 indicates moderate neuropathy, and tertile 3 indicates more severe neuropathy. This symptom questionnaire aspect of the DELCaP study was not initiated until after the study began; thus, 922 patients completed the FACT/GOG-Ntx.
Baseline characteristics for participants with CTCAE grade 0 to 2 and grade 3 or 4 neuropathy, and by tertile of FACT/GOG-Ntx, were compared using chi-square tests. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression for associations between each dietary supplement and CTCAE neuropathy, with ordinal regression for higher compared with lower neuropathy assessed via FACT/GOG-Ntx. Patients were classified as supplement users if they took a particular supplement at least once a week.
We used separate models to examine supplement use before diagnosis and during treatment in relation to neuropathy. We then considered use before and during treatment jointly. Because of low use of many individual supplements included in the questionnaires, we present data only on those with at least 10% use at any time point. Self-reported height and usual weight before diagnosis were used to compute body mass index (BMI) in kg/m2. Odds ratios were a priori–adjusted for age at completion of first questionnaire, BMI, race/ethnicity, smoking status, alcohol use, physical activity, and treatment arm. We considered menopausal status, education, and consumption of fruits and vegetables, as well as total cumulative dose and treatment modification, as covariates, but inclusion did not appreciably affect risk estimates, so they were excluded from final adjusted models. Model fit for logistic regression was assessed via Hosmer-Lemeshow tests, and the proportional odds assumption for ordinal models was assessed graphically. There was no evidence of poor fit (all P > .05). All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
The characteristics of DELCaP participants by CTCAE toxicity grade and by tertile of FACT/GOG-Ntx scores are shown in Table 1. Grade 3 and 4 CTCAE neuropathy, observed in 12.4% of patients, was more common among African Americans and among patients randomly assigned to treatment arms with a biweekly paclitaxel dose of 175 mg/m2 (arms 1, 2, and 5) for six cycles than those in arms 3, 4, and 6. Using FACT/GOG-Ntx scores, neuropathy was more common in patients who were older, nonwhite, overweight and obese, former or current smokers, and those with less education than a college degree; 65.5% of patients with CTCAE-assessed grade 3 or 4 were in the highest tertile of FACT/GOG-Ntx neuropathy, compared with 30.3% of patients with CTCAE-assessed grade 0 to 2 toxicities.
Individual components of the FACT/GOG-Ntx subscale are displayed in Figure 2. “Quite a bit” and “very much” were grouped together to represent severe neuropathy, “somewhat” was considered moderate, and “a little bit” was considered mild. Foot numbness was the most common symptom, with 81.9% of patients experiencing at least mild foot numbness and 52.3% reporting severe foot numbness (Figure 2). Hand numbness was also very high, with 79.1% reporting at least mild hand numbness; 74.5% reported foot discomfort, and 66.7% reported hand discomfort.
Individual components of Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity. “Quite a bit” and “very much” were grouped together to represent severe neuropathy. “Somewhat” was considered moderate, and “a little bit” was considered mild.
As shown in Table 2, patients who used multivitamins before diagnosis were 39.7% less likely to experience CTCAE grade 3 or 4 neuropathy than nonusers (adjusted odds ratio [aOR] = 0.60, 95% CI = 0.42 to 0.87) and, according to FACT/GOG-Ntx, were 21.9% less likely to report more neuropathy than nonusers (aOR = 0.78, 95% CI = 0.61 to 1.00). Use of vitamin C, folic acid, calcium, iron, and fish oil before diagnosis was not associated with CTCAE grade 3 or 4 neurotoxicity. There were no statistically significant associations between use of any individual supplements prior to diagnosis and CIPN assessed by CTCAE or by FACT/GOG-Ntx.
Table 3 shows associations between neurotoxicity and use of supplements during chemotherapy. Odds of CTCAE grade 3 or 4 neuropathy were lower for patients who reported use of multivitamins during treatment compared with nonusers (aOR = 0.73, 95% CI = 0.49 to 1.08), as well as for users of fish oil, EPA, omega-3, flaxseed, or cod liver oil (aOR = 0.54, 95% CI = 0.28 to 1.06), although associations were not statistically significant. None of the other supplements was statistically significantly associated with likelihood of grade 3 or 4 neuropathy. Although not statistically significant, the use of iron during treatment appeared to be associated with increased odds of grade 3 or 4 neuropathy (aOR = 1.67, 95% CI = 0.92 to 3.03). Multivitamin use during treatment was also associated with lower odds of neuropathy according FACT/GOG-Ntx (aOR = 0.77, 95% CI = 0.60 to 0.99), and use of vitamins B6 and B12 with higher odds, although associations were not statistically significant.
Assessing use both before and during treatment (Supplementary Table 1, available online), compared with nonusers, patients who used multivitamins before diagnosis as well as those who used both before and during treatment were at reduced odds of grade 3 and 4 neuropathy. None of the other supplements was statistically significantly associated with CTCAE neuropathy. Results were somewhat similar when classifying neuropathy according to the FACT-GOG/NTX (Supplementary Table 2, available online).
In this study of breast cancer patients enrolled in a large cooperative group clinical trial comparing dosing regimens of doxorubicin, cyclophosphamide, and paclitaxel, we observed associations between multivitamin use both before and during treatment and lower odds of neuropathy assessed by CTCAE and FACT/GOG-Ntx. Associations were strongest in patients using multivitamins both before diagnosis and during chemotherapy. There was a statistically nonsignificant association between iron use during treatment and increased neuropathy. Use of iron may have been initiated during chemotherapy to relieve treatment-induced anemia. We did not observe any statistically significant associations with use of other supplements.
To our knowledge, this is the first study embedded in a therapeutic trial to evaluate the association between dietary supplement use and taxane-induced CIPN. There are several possible explanations to account for the fact that we observed statistically significant associations with multivitamin use but no associations with individual supplements. First, multivitamin use was much higher than use of individual supplements, providing more statistical power to detect a statistically significant association. Therefore, while the association with multivitamin use could be driven by one or more individual components of multivitamins, we would have been less likely to observe a statistically significant association with use of single vitamins. Although few studies have evaluated the relationships between individual supplements and CIPN, some data exist to support this explanation. For example, small trials of omega-3 fatty acid supplementation and of vitamin E found associations with reduced CIPN symptoms, although no association with vitamin E was observed in a larger placebo-controlled, multicenter phase III trial. Conversely, however, a well-designed randomized clinical trial of acetyl-L-carnitine was unexpectedly associated with increased CIPN, and a recent observational follow-up study of a cohort of breast cancer survivors found that initiation of antioxidant supplements during treatment was associated with increased odds of CIPN. However, it is unknown if this association reflects a causal relationship or if patients began use of antioxidant supplements in an effort to reduce symptoms. Disparate results across studies and trials highlight the complexity of relationships between neuropathy and individual supplements, possibly indicating that one supplement alone may not be efficacious in treating symptoms of neuropathy. Such synergy could account for our findings; two or more individual multivitamin components, effective only in combination, could be driving the statistically significant association with multivitamin use. We were unable to evaluate this possibility, however, because of the small numbers of participants who reported individual supplement use. To our knowledge, only one study, of diabetic neuropathy, has evaluated the effect of multiple supplement use. In that placebo-controlled randomized trial, participants received either zinc, magnesium, and vitamins C and E or these supplements plus vitamins B1, B2, and B6, biotin, and folic acid. Compared with a placebo-only group, the two supplement groups experienced reduced symptoms of neuropathy, supporting the hypothesis that supplements may have synergistic effects.
Confounding due to lifestyle factors is another possible explanation for our findings. Participants taking multivitamins may have also engaged in other behaviors that may reduce the odds of developing CIPN. There are limited epidemiologic data regarding risk factors for CIPN, but we adjusted for the potential confounding effects of age, BMI, race, smoking status, physical activity, alcohol intake, and treatment arm in multivariable models. A recent study of cancer patients receiving taxane treatment noted that diabetes was associated with a twofold increase in odds of CIPN. It is possible that multivitamin users may have been more health conscious, with a lower prevalence of diabetes. While we did not have information regarding diabetes, we did control for BMI, which may have reduced some of the potential confounding; however, our results could nonetheless have been affected by uncontrolled confounding.
A limitation of this study is that it relies on the use of self-report to assess supplement use, which could introduce measurement error. Use of dietary supplements was queried with self-administered questionnaires, and thus we do not have objective data, such as blood markers, with which to conduct sensitivity analyses or statistically correct for potential measurement error. However, patients who participated were highly motivated and were asked to collect their vitamins for recording ingredients and dosages, particularly those taken during chemotherapy. Thus, we have some degree of confidence that self-reports of usage in this study are fairly accurate. Furthermore, we did not collect data regarding the actual form of certain supplements, such as vitamin E, that participants regularly consumed. This could mask the effect of a more active form of a supplement, should one truly exist. Another limitation is that, while supplement use questions referred to use during treatment, we are unable to determine if patients began supplement use before paclitaxel administration or after. It is possible that some participants initiated supplement use after symptoms arose in an attempt to alleviate those symptoms. This would attenuate a true positive association and strengthen a true inverse association. Additionally, for some supplements, use was very low, increasing the possibility of false negatives. Another potential limitation is the assessment of CIPN via CTCAE, which could be prone to poor interobserver agreement and underestimation of CIPN. Nevertheless, because neuropathy is physician-assessed, any misclassification is unlikely to vary by supplement use and would bias results toward the null. Because sites were not required to report grade 1 or 2 neuropathies, we were unable to examine the association between supplement use and mild or intermediate neuropathies with the CTCAE, but use of the self-reported FACT/GOG-Ntx allowed us to capture a broader range of neuropathies. We noted similarities in associations between neuropathies and supplements using both measures. Multivitamin use before diagnosis and use during treatment were each associated with decreased CIPN, regardless of which measure was used.
We were also unable to assess nutritional status of patients at baseline. It is possible that multivitamin nonusers could have been deficient in some nutrients compared with users; in that case, multivitamin use could be a proxy for vitamin sufficiency and could account for the observed association. Finally, as in any observational study, our findings could be due to chance, particularly due to the fact that associations with multiple factors were tested. Only a randomized clinical trial of vitamin supplements could assess the direct effects of supplement use on cancer treatment outcomes.
A notable strength of this study, compared with epidemiological population studies of cancer patients, is that it was conducted in the context of a clinical trial, wherein patients with similar tumor characteristics were treated with the same agents, with entry into the DELCaP study at the time of registration to the trial. This enabled us to collect and record use prior to and at the time of diagnosis before patients began treatment, reducing the likelihood of recall bias if behaviors changed with chemotherapy. Furthermore, neurotoxicities were reported by each site prospectively according to CTCAE criteria, again standardizing measurement of this phenotype. However, because of the nature of cooperative group clinical trials, we were unable to obtain detailed information regarding dose modifications that individual patients may have received because of taxane-related side effects. Clinical sites were only required to report information critical to the major objectives of the parent trial, and thus only the most severe grade of toxicity and occurrence of dose reduction were captured. Because we do not know the reason for any potential dose modification or the amount by which doses may have been reduced, it is not possible to link modifications to the timing or existence of CIPN. However, when we included cumulative paclitaxel dose and treatment modification in multivariable models of supplement use and neurotoxicity, risk estimates were not appreciably changed. Prospective studies incorporating detailed information on timing of dose modifications as well as supplement use are warranted to understand the potential relationships between supplement use and the experience of CIPN.
Future studies are needed to replicate this finding as well as to better understand which components of multivitamins could be primarily responsible for the observed reduction in risk of CIPN, or if the associations are affected by potential confounding. Importantly, the potential associations between use of supplements and observed treatment side effects need to be balanced against what, if any, influence vitamin use, particularly during chemotherapy, may have on recurrence and survival in breast cancer patients. With longer follow-up and additional events in S0221, it will be of interest to examine these associations. If results indicate that there are no adverse effects of dietary supplements on cancer outcomes, randomized trials could be justified to determine if specific supplements can be used to reduce treatment-related side effects. Without these types of rigorous prospective studies, changes to clinical practice or recommendations for use of vitamin supplements are clearly not warranted.
This work was supported by R01 CA116395 (CBA), R01 CA139426 (CBA), the Breast Cancer Research Foundation (CBA), and National Cancer Institute grant P30CA016056 to Roswell Park Cancer Institute. S0221 is supported, in part, by National Cancer Institute (NCI)/Division of Cancer Prevention SWOG NCORP Research Base grant 5UG1CA189974-02; by NCI and National Clinical Trials Network grants CA180888, CA180819, CA180863, CA180858, CA180828, CA180801, CA68183, CA04919, CA13612, CA46282; and by Amgen, Inc.
The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.